Therapeutics News and Research

RSS

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

RedPath Integrated Pathology, Inc., a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has entered into a binding agreement to be acquired by ExonHit Therapeutics, S.A., a leading French diagnostics and therapeutics biotech company for an upfront payment of $12.5M in cash and $10M in stock, and starting in 2012, subsequent additional payment up to $9.5M dependent on the achievement of sales targets.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.

26 Apr 2010

Avecia Biotechnology reaches agreement with Pfizer to market Macugen

Avecia Biotechnology, Inc., a leading provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached agreement with Pfizer Inc. regarding the commercial supply of a key component of Macugen (pegaptanib sodium injection), marketed in the E.U. by Pfizer for the treatment of wet Age-Related Macular Degeneration.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor's novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

26 Apr 2010

Mirina closes Versant led Series A-1 financing

Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.

26 Apr 2010

CBSA hosts Career and Resource Fair for students and job seekers

The Colorado BioScience Association is hosting its second annual Career and Resource Fair Wednesday, April 28, from 1 to 4 p.m. at the Jefferson County Fairgrounds. The event will bring together students and job seekers looking to learn more about bioscience industry employment and training opportunities in the state.

24 Apr 2010

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.

24 Apr 2010

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

24 Apr 2010

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

InVivo Therapeutics Corporation CEO Frank Reynolds will be honored by the Irish Voice and Irish America Magazine, in collaboration with the Irish Government, as one of the 'Irish Life Science 50.' The award is the first honor to be given to influential Irish Americans for their work in the field of life sciences and is aimed to recognize "diverse accomplishments and advancements in the industry," according the Irish Voice.

23 Apr 2010

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

The Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable "factory" that uses natural (non-genetically-modified) green plants to efficiently produce large quantities of vaccines and therapeutics within weeks.

23 Apr 2010

European Patent Office intends to grant patent for Intezyne's IVECT Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne's breakthrough drug delivery technology, the IVECT Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues.

23 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a poster at the American Association for Cancer Research's 101st Annual Meeting 2010 that details their novel study of molecules that use a tumor's acidic microenvironment to help them tailor chemotherapeutic agents to kill the tumor.

23 Apr 2010

Therapeutics News and Research

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Stinging FDA review for Acurox – the implications

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Avecia Biotechnology reaches agreement with Pfizer to market Macugen

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

National Securities, MD Becker Partners to host SCIENCE program

Mothers with preeclampsia at reduced risk of developing breast cancer

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Mirina closes Versant led Series A-1 financing

CBSA hosts Career and Resource Fair for students and job seekers

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

European Patent Office intends to grant patent for Intezyne's IVECT Method

Researchers take major step to predict adverse drug reactions using genetic information

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News